布地奈德/福莫特罗治疗轻、中度哮喘临床研究

目的:比较低剂量的布地奈德/福莫特罗(信必可都保)与中等剂量的布地奈德干粉(普米克都保)吸入治疗成年轻、中度哮喘患者的临床疗效和安全性。方法:62例哮喘患者分为A、B组,A组吸入信必可都保,B组吸入普米克都保,对照观察日间症状、夜间症状、最大呼气流量(PEF)、速效β2受体激动药使用次数的变化和不良反应。结果:2组治疗后日间症状和夜间症状(夜间憋醒次数)均有显著改善,速效β2受体激动药用量减少,PEF值及肺功能均有明显改善,且组间比较差异显著,不良反应轻微。结论:联合吸入低剂量的糖皮质激素和长效β2受体激动药为控制哮喘的较佳方案。加入低剂量长效β2受体激动药的疗效优于单一提高糖皮质激素的用量。

Budesonide/Formoterol in the Management of Patients with Mild or Moderate Asthma: Clinical Research

OBJECTIVE: To evaluate the efficacy and the safety of low dose budesonide/formoterol combination therapy vs.medium dose of budesonide(BUD) dry powder in the management of mild or moderate adult asthma.METHODS: A total of 62 patients with asthma were randomized to Group A(budesonide plus formcterol) or Group B(budesonide).Main outcome measures: daytime symptom and nocturnal symptom,peak expiratory flow(PEF),number of times of using rapid-acting β 2 agonist and its ADR.RESULTS: After treatment,both groups had significant improvement in daytime symptom and nocturnal symptom(number of times of wakeup),PEF value and lung function,and the dosage of rapid-acting β 2 agonist was decreased,showing significant differences between the two groups.The ADR was light in degree.CONCLUSION: Inhalation therapy of low dose of glucocorticoid plus long-acting β 2 agonist is an optimal choice in the management of asthma.The efficacy of glucocorticoid could be enhanced more by combination with low dose and long-acting β 2 agonist than by simply increasing its own dose.